Sector
PharmaceuticalsOpen
₹150.65Prev. Close
₹153.7Turnover(Lac.)
₹6.03Day's High
₹150.65Day's Low
₹150.6552 Week's High
₹052 Week's Low
₹0Book Value
₹7.84Face Value
₹10Mkt Cap (₹ Cr.)
171.14P/E
0EPS
0.19Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Equity Capital | 11.36 | 11.36 | 3.84 | 3.76 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -2.57 | -2.71 | -3.19 | -2.87 |
Net Worth | 8.79 | 8.65 | 0.65 | 0.89 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Revenue | 0.1 | 0.13 | 0.2 | 0.24 |
yoy growth (%) | -24.66 | -34.3 | -13.52 | |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.06 | -0.06 | -0.18 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Profit before tax | 0.13 | -0.15 | -0.31 | -0.04 |
Depreciation | 0 | 0 | 0 | -0.03 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.13 | 8 | 0.59 | |
Other operating items |
| Y/e 31 Mar | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -24.66 | -34.3 | -13.52 | |
Op profit growth | -50.8 | -49.06 | 4,095.3 | |
EBIT growth | -189.95 | -51.71 | 571.94 | |
Net profit growth | -189.95 | -51.71 | 571.94 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,686.25 | 128.43 | 4,04,587.86 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,940.85 | 76.08 | 1,57,710.9 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,512 | 26.24 | 1,22,115.23 | 1,438.15 | 0.86 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238 | 60.07 | 1,09,583.71 | 485 | 0.86 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,497.8 | 53.29 | 1,03,053.87 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Mani Murugadoss Rao
Director
Shantilal Purohit
Director
Anitha Mahesh
Chairman & Managing Director
BVS Kotewara Rao
Additional Director
Sanjay Kr Choradia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Mahavir Advanced Remedies Ltd
Summary
Incorporated in 1992, Indo American Advance Pharmaceuitcals (IAAPL) is promoted by V Koteswara Rao, B V S Kkoteswara Rao and T Ramakrishna.The company is now setting up a project for manufacturing variety of formulations -- tablets, capsules, liquids and ointments in allopathic and ayurvedic/siddha division in the field of antibiotics, antibacterials, analgesics, anti-pyretics, anti-inflammatory, etc, both as branded and generic products. To part-finance the above project, IAAPL came with a public issue of Rs 2.75 cr.
Read More
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
